Today, 80 is the new 70
Transcatheter aortic valve implantation (TAVI) patients in their 70s and 80s showed comparable quality-of-life (QoL) improvements and clinical benefits1
Read moreInterventional options and guidelines are continually evolving in aortic stenosis (AS). Access the key updates on aortic stenosis management in the 2021 ESC/EACTS guidelines, including the evidence that supported this change and the importance of a shared decision-making process with your patients.
2021 ESC/EACTS guidelines in practice
TF-TAVI is now a Class IA recommendation, for patients with severe aortic stenosis (sAS) ≥75 years of age**, as well as for additional patient groups < 75 years of age.1 Read more about the changes and how they could impact your everyday clinical practice.
**Based on evaluation of clinical, anatomical and procedural factors
Read more
Diagnosing aortic stenosis patients
The ESC/EACTS guidelines continue to recommend echocardiography as a key tool in confirming AS diagnosis and severity, guiding treatment choices and indicating when intervention is needed.1
Read more
Transfemoral TAVI (TF-TAVI) procedure using balloon-expandable technology with
Interventional options for aortic valve replacement (AVR)
The updated 2021 ESC/EACTS Guidelines for the treatment of sAS highlight the role of the Heart Team and patient choice on treatment decisions.1
Find out more about the current treatment options for your patients with sAS, and considerations of the Heart Team when deciding between TAVI and surgery (SAVR).
Read moreReferences:
1 Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab39.
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-0762 v3.0